Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.

Christina Rautenberg Michael Lauseker Jennifer KaiversPaul JägerCarolin FischermannsSabrina PechtelRainer HaasGuido KobbeUlrich GermingThomas Schroeder

Published in: European journal of haematology (2021)

PB WT1 expression represents a useful method to estimate pretransplant MRD, which is highly predictable for post-transplant outcome and may help improving peri-transplant management in AML/MDS patients.

Keyphrases

peripheral blood
acute myeloid leukemia
newly diagnosed
ejection fraction
poor prognosis
heavy metals
prognostic factors
patient reported outcomes